FDA warned Ivermectin24h.com for selling hydroxychloroquine online without prescriptions and claiming it treats COVID-19.
What happened
FDA reviewed the website www.ivermectin24h.com on December 13, 2021. FDA found the homepage asked “Worried about CORONAVIRUS?” and a “BUY NOW” button led to a page selling “Hydroxychloroquine,” which the site said treats malaria, lupus, and rheumatoid arthritis. FDA said the site offered this prescription drug without requiring a prescription and made claims about uses for which FDA has not approved it, including COVID-19.
What FDA found
The website offers hydroxychloroquine, a prescription drug, without requiring a prescription, so the drug is misbranded.
section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]The website claims hydroxychloroquine can treat COVID-19 even though FDA has not approved it for that use.
section 503(b) of the FD&C Act [21 U.S.C. § 353(b)]Offering the misbranded drug for sale to U.S. consumers causes it to be introduced into interstate commerce.
section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]Dispensing a prescription drug without a prescription results in the drug being misbranded while held for sale.
section 301(k) of the FD&C Act [21 U.S.C. § 331(k)]
What FDA wants
Within 48 hours, FDA asks the company to email FDA describing the specific steps taken to address the violations and prevent recurrence. If corrective action cannot be completed within 48 hours, the company must state the reason for delay and when it will complete the corrections.
Who should pay attention
- online pharmacies selling prescription drugs
- consumers seeking COVID-19 treatments online
- companies making unapproved drug claims on websites
This is a summary. Read the original letter on fda.gov.